GLP-1RA users were younger (71.9 vs. 77.8 years, <i>p</i> < 0.001), had lower hypertension prevalence (61.2% vs. 78.4%, <i>p</i> = 0.02), and were more frequently on insulin (69.4% vs. 25.5%, <i>p</i> < 0.001) and sodium-glucose cotransporter 2 inhibitors (55.1% vs. 28.1%, <i>p</i> = 0.001). Here, SLC5A2 is linked to Hypertension.